Park Geun Ho, Shinn Helen Ki, Kang Ju-Hee, Na Won Ju, Kim Young Hyo, Park Chang-Shin
Department of Pharmacology, Hypoxia-Related Disease Research Center, Inha Research Institute for Medical Sciences, Inha University College of Medicine, Incheon, Korea.
Department of Anesthesiology and Pain Medicine, Inha University College of Medicine, Incheon, Korea.
Int Neurourol J. 2016 Jun;20(2):114-21. doi: 10.5213/inj.1632578.289. Epub 2016 Jun 24.
To evaluate the effect of anti-interleukin-33 (anti-IL-33) on a mouse model of ovalbumin (OVA)-induced acute kidney injury (AKI).
Twenty-four female BALB/c mice were assigned to 4 groups: group A (control, n=6) was administered sterile saline intraperitoneally (i.p.) and intranasally (i.n.); group B (allergic, n=6) was administered i.p./i.n. OVA challenge; group C (null treatment, n=6) was administered control IgG i.p. before OVA challenge; and group D (anti-IL-33, n=6) was pretreated with 3.6 µg of anti-IL-33 i.p. before every OVA challenge. The following were evaluated after sacrifice: serum blood urea nitrogen and creatinine levels, Kidney injury molecule-1 gene (Kim-1) and protein (KIM-1) expression in renal parenchyma, and expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), phosphorylated endothelial NOS (p-eNOS), and phosphorylated AMP kinase (p-AMPK) proteins in renal parenchyma.
After OVA injection and intranasal challenge, mice in groups B and C showed significant increases in the expression of Kim-1 at both the mRNA and protein levels. After anti-IL-33 treatment, mice in group D showed significant Kim-1 down-regulation at the mRNA and protein levels. Group D also showed significantly lower COX-2 protein expression, marginally lesser iNOS expression than groups B and C, and p-eNOS and p-AMPK expression at baseline levels.
Kim-1 could be a useful marker for detecting early-stage renal injury in mouse models of OVA-induced AKI. Further, anti-IL-33 might have beneficial effects on these mouse models.
评估抗白细胞介素-33(抗IL-33)对卵清蛋白(OVA)诱导的小鼠急性肾损伤(AKI)模型的影响。
将24只雌性BALB/c小鼠分为4组:A组(对照组,n = 6)腹腔内(i.p.)和鼻内(i.n.)给予无菌生理盐水;B组(过敏组,n = 6)腹腔内/鼻内给予OVA激发;C组(空白治疗组,n = 6)在OVA激发前腹腔内给予对照IgG;D组(抗IL-33组,n = 6)在每次OVA激发前腹腔内给予3.6 μg抗IL-33进行预处理。处死小鼠后评估以下指标:血清血尿素氮和肌酐水平、肾实质中肾损伤分子-1基因(Kim-1)和蛋白(KIM-1)的表达,以及肾实质中环氧化酶-2(COX-2)、诱导型一氧化氮合酶(iNOS)、磷酸化内皮型一氧化氮合酶(p-eNOS)和磷酸化AMP激酶(p-AMPK)蛋白的表达。
在OVA注射和鼻内激发后,B组和C组小鼠肾实质中Kim-1在mRNA和蛋白水平的表达均显著增加。抗IL-33治疗后,D组小鼠肾实质中Kim-1在mRNA和蛋白水平均显著下调。D组COX-2蛋白表达也显著降低,iNOS表达略低于B组和C组,p-eNOS和p-AMPK表达恢复至基线水平。
Kim-1可能是检测OVA诱导的AKI小鼠模型早期肾损伤的有用标志物。此外,抗IL-33可能对这些小鼠模型具有有益作用。